Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
8 Results for "
B-cell malignancy models
" in MedChemExpress (MCE) Product Catalog:
Products (8)
8 Results for "B-cell malignancy models" in MCE Product Catalog:
Target:
Research Areas:
Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .
Synonyms: BMF-219; Menin-MLL inhibitor 21
Target:
Research Areas:
Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes .
Cat. No.: HY-P9959
CAS No.: 635715-01-4
Synonyms: CMC-544; PF-5208773; WAY-207294
Target:
Research Areas:
Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22 + B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia .
Cat. No.: HY-168983
CAS No.: 2952589-57-8
Target:
Research Areas:
Lonitoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Lonitoclax has comparable anti-tumor efficacy to Venetoclax (HY-15531) in both B cell and myeloid malignancy models. Lonitoclax is promising for research of relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and certain low-grade lymphomas .
Cat. No.: HY-P991542
CAS No.: 1931954-95-8
Cat. No.: HY-P991935
Cat. No.: HY-P9959A
CAS No.: 635715-01-4
Synonyms: CMC-544 (solution); PF-5208773 (solution); WAY-207294 (solution)
Target:
Research Areas:
Inotuzumab ozogamicin solution (CMC-544 solution) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin solution and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin solution has demonstrated efficacy against CD22 + B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin solution can be used in the research of acute lymphoblastic leukemia .
Cat. No.: HY-184007
CAS No.: 3121287-19-9
PROTAC BCL6 Degrader-4 is a potent PROTAC BCL6 degrader. PROTAC BCL6 Degrader-4 recruits CRBN E3 ligase machinery to promote ubiquitination and proteasomal degradation of BCL6. PROTAC BCL6 Degrader-4 can be used for the research of diffuse large B-cell lymphoma and related hematological malignancies .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
